Tammuella Chrisentery-Singleton/LinkedIn
Aug 8, 2026, 20:37
Tammuella Chrisentery-Singleton: What Comes Next for Hemophilia Care With Non-Factor Therapies?
Tammuella Chrisentery-Singleton, Chief Science Officer at American Thrombosis and Hemostasis Network (ATHN), Co- Director Hemostasis and Thrombosis Program at Ochsner Health, shared a post on LinkedIn:
“After the long trip home from ISTH, I’m excited to bring new insights back to the clinic as we think about what comes next for
hemophilia care with non-factor therapies now being available across the world.
Note: This content is intended for healthcare professionals only.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 12:37Dan Milikovsky: Uncovering Cerebrovascular Injury in Sickle Cell Disease
-
Sep 29, 2026, 12:02Hajra Malik: Bridging Language Gaps in Hematology With AI
-
Sep 29, 2026, 11:57Joan Montaner: Can Blood Test Identify Intracerebral Hemorrhage Within Minutes?
-
Sep 29, 2026, 11:43From Years Without Answers to Life With Hemophilia Care – WFH
-
Sep 29, 2026, 11:32Sara Al Dallal: Transforming Hemophilia Care Across the Gulf
-
Sep 29, 2026, 11:21Richard Davis: Rapid Rescue in Massive Pulmonary Embolism
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate
-
Sep 29, 2026, 10:54How Does Haemophilia Affect Motor Development in Infants? – EAHAD